Vaccine and Infectious Disease Division
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, remains one of the 3 most deadly infections globally. Current preventive (vaccine) and therapeutic (antibiotic) resources for tuberculosis exist, but have been inadequate to significantly reduce disease burden. Co-infection with HIV has increased the incidence of and mortality from both diseases and this interaction has spurred interest in implementation of integrated health care services. VIDD scientists are developing mathematical modeling tools in combination with clinical trial design for studying the effects of potential prevention and therapeutics on morbidity and mortality from tuberculosis.
Design and analysis of trials for HIV prevention, joint models for longitudinal and survival data and
statistical methods in HIV/AIDS and cardiovascular research.
Phone: (206) 667-1731
Fax: (206) 667-4812
Characterizing T cells induced by candidate vaccines using flow cytometry. Developing new assays to evaluate vaccine efficacy with HIV Vaccine Trials Network. Studies include examining T cell function at the single-cell level using advanced flow cytometric techniques; examples include T cell responses to vaccination and to viral infections such as CMV, EBV, HIV, and hepatitis B.
Elucidating cellular mechanisms for control of HIV replication, Assessing cellular immune responses in HIV vaccine recipients, Teaching and Mentoring Interests, HIV immunology for experts and the public
Research focus: Design and analysis of clinical trials
Phone: (206) 667-5780
Fax: (206) 667-4378
Research centers on developing an HIV vaccine and investigating the complex relationship between HIV and the immune system and the influence of antiretroviral therapy.
Research interests include the study and manipulations of CD8 T cells and NK cells, the mechanism for T cells becoming memory T cells and the therapeutic potential of NK cells to protect from opportunistic infections following transplantation